PowerPoint Presentation

Published on Slideshow
Static slideshow
Download PDF version
Download PDF version
Embed video
Share video
Ask about this video

Scene 1 (0s)

Pfizer Logo change in all slides. P zer LEADING WITH A PURPOSE 1026 AM (x 4/4/2022.

Scene 2 (8s)

Logo change. Pfizer vertical vidK) Deliver first-in-class science 1027 AM 4/4/2022.

Scene 3 (16s)

Logo change. Pfizer vertica final p zer Deliver first-in-class science Source the best science in the world. Double our innovation success rate U)13 4/4/2022.

Scene 4 (26s)

Remove. Pfizer vertical final Video of Mia in Irdia Addressing current disease challenges and bringing tomorrow's cures to India. Ct19 TAM 4/4/2022.

Scene 5 (36s)

Logo change. Pfizer final p zer IPlGzel'fi How Pfizer is making a difference in the management of infections Active stewardship: ensure patients receive the correct antibiotic an r ura on TUAM 4/4/2022.

Scene 6 (47s)

Logo change. Pfizer vertical Final video P zel' How Pfizer is making a difference in the management of infections Innovative surveillance tools: to help physicians better curren res ncepa ms l&28AM (x 4/4/2022.

Scene 7 (58s)

Logo change. Pfzer vMical final How Pfizer is making a difference in the management of infections Diverse portfolio: medicines to treat and prevent Serious n c nS e wo co•43 11129 AM 4/4/2022.

Scene 8 (1m 9s)

Magnex 1 st , 2 nd Meronem and 3 rd Zosyn – check if all logos are correct. All logos sent.

Scene 9 (1m 20s)

Update Pfizer Logo. Pfizer vertical Final video p zer Comprehensive Product Portfolio Any-Bacterial Agents DalacinC IBOAM (x 4/4/2022.

Scene 10 (1m 29s)

1 st Cresemba , 2 nd Eraxis , 3 rd Vfend – Check all logos are correct. Sent all logos already.

Scene 11 (1m 41s)

Check if all logos are correct. Sent all logos already.

Scene 12 (1m 52s)

Update Pfizer logo. Pfizer vertical Final video p zer Anti•lnfectives COMMITMENT TOWARDS NEWER INNOVATIVE ANTIBIOTICS (x 4/4/2022.

Scene 13 (2m 1s)

Replace this content with Zavicefta content I have sent – Added in the next 2 slides.

Scene 14 (2m 14s)

Zaviceft a.

Scene 15 (2m 21s)

Ceftazidime- avibactam. Ceftazidime- Third generation cephalosporin Avibactam- non beta lactam- beta lactamase inhibitor First-in-class Inhibition of β-lactamases is covalent but reversible (characteristic that other known β-lactamase inhibitors lack) The activity of AVI is reinstated once acted.

Scene 16 (2m 46s)

Ceftazidime – avibactam indications & spectrum of activity.

Scene 17 (3m 33s)

Replace this content with Zavicefta content I have sent – Added in the next 2 slides.

Scene 18 (3m 46s)

After Zavicefta , Add cresemba slides. Pfizer vertical Final video Anti•lnfectives Decisive action against gram negative pathogens including E. coli, K.pneumoniae&P eruginosag 01:15 (x 4/4/2022.

Scene 20 (4m 0s)

CRESEMBA® IS THE ONLY AZOLE LICENSED FOR TREATMENT OF BOTH INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS.

Scene 21 (4m 30s)

Isavuconazole formulations, strengths and dosage.

Scene 22 (4m 55s)

After Cresemba , replace existing Zinforo slides with new slides.

Scene 24 (5m 15s)

Salient Features. Indicated for the treatment of adult (≥18 years of age) patients with Community-acquired pneumonia and Complicated skin and soft tissue infections ( cSSTI ) 1 First MRSA-active β -lactam with extended spectrum against Gram-positive and Gram-negative bacteria commonly associated with cSSTI 2 Early rapid clinical response by day 3 in cSSTI as recorded in various Trials (CANVAS and COVERS) 3 Day 4 early response in CAP as seen in trials FOCUS 1 and 2. 4,5 Recently recommended in cSSTI as per the Surgical Infectious Society Guideline as the first choice of drug for the management of MRSA SSTI 6.

Scene 25 (6m 10s)

Dosage in Adults and Renal Impairment. Simple dosing with no routine monitoring, low risk of drug–drug interaction, no dose adjustment based on bodyweight.

Scene 26 (6m 56s)

After Zinforo, will be Atlas. Replace Pfizer logo.

Scene 27 (7m 6s)

Replace Atlast content with new content added in the next 3 slides.

Scene 29 (7m 26s)

Antimicrobial Testing Leadership and Surveillance (ATLAS): Pfizer’s landmark surveillance database.

Scene 30 (7m 56s)

ATLAS: Key Features. Heatmaps: interactive heatmaps illustrating antimicrobial resistance and phenotypic distribution of isolates Database: MIC distribution, susceptibility and resistance data on various pathogens Provide real-time in vitro susceptibility data on a breadth of antibiotics Data can be exported in spreadsheet format or images (including graphs and tables) Data can be searched based on EUCAST or CLSI breakpoints using filters: countries, regions, genus, species, years, phenotype, genotype, ward source (emergency room, ICU, surgery, clinic, etc.), specimen source (body fluids, CNS, GI, lymph, etc.).

Scene 31 (8m 35s)

Remove the references from here and add it at the end of the video. References of the content can be mentioned either beneath each slide or all together in the end.

Scene 32 (8m 51s)

Pfizer vertical final ideo COMMITMENT TOWARDS MEDICAL EDUCATION A global education resourc to provide support for managing local _challenaesimthetreatmentof_ serious infections in the Indian 0303 1040 AM (x 4/4/2022.

Scene 33 (9m 3s)

The #joyofdigital at Pfizer.

Scene 34 (9m 9s)

Omnichannel touchpoints. Omnichannel project. Doctor Network Platform promotions.

Scene 35 (9m 27s)

Start now http://indiamcs.in. “India MCS” Brought to you by Pfizer – A unique immersive experience for HCPs in form of video case stories & quizzes..

Scene 36 (9m 39s)

A one stop solution. Web portals for HCPs. Pfizer for professionals.

Scene 37 (9m 52s)

Gamification project on Anti-microbial Stewardship.

Scene 38 (10m 11s)

Customised Video detailing. Recorded video messages are shared with healthcare professionals via a customized email.

Scene 39 (10m 21s)

Pfizer vertical final ideo COMMITMENT TOWARDS MEDICAL EDUCATION A global education resourc to provide support for managing local _challenaesimthetreatmentof_ serious infections in the Indian 0303 1040 AM (x 4/4/2022.